APYX

Apyx Medical Corp (APYX) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Apyx Medical Corporation is an advanced energy technology company focused on the Helium Plasma Platform Technology, marketed as Renuvion (cosmetic surgery) and J-Plasma (hospital surgical). The company operates two segments: Advanced Energy and OEM. In May 2025, the company received FDA 510(k) clearance for the AYON Body Contouring System, with a commercial launch planned for the second half of 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total sales decreased 6.4% QoQ and 7.1% YTD compared to the prior year. The OEM segment saw a significant decline of 28.5% (Q2) and 37.3% (YTD) due to lower volume from existing customers, including Symmetry Surgical. The Advanced Energy segment was relatively flat (-1.0% Q2) but grew 2.0% YTD.
• Cost Reductions: Operating expenses decreased significantly due to a workforce reduction of nearly 25% implemented in November 2024. Salaries and related costs dropped 34.4% YTD. R&D expenses fell 42.3% YTD.
• Improved Loss Profile: Net loss attributable to stockholders narrowed by 42% in Q2 and 44% YTD compared to the prior year periods, driven by cost-cutting measures.
• Working Capital: Working capital decreased from $45.7M (Dec 31, 2024) to $39.3M (June 30, 2025), primarily due to cash burn and inventory increases.

Guidance, Outlook, and Risks

• Product Launch: The company is preparing for the commercial launch of the AYON Body Contouring System in H2 2025. Pre-orders for the system (including the Apyx One Console) were taken in Q2 2025.
• Market Dynamics: Management notes that GLP-1 weight loss drugs initially negatively impacted plastic surgery revenue but may eventually drive demand for body contouring procedures to address loose skin, a key use case for Renuvion.
• Liquidity & Debt Covenants: The company maintains a $37.5M term loan with Perceptive Credit Holdings. An amendment in Nov 2024 set revenue targets for the Advanced Energy segment ($37.0M for 2025) and a maximum operating expense covenant ($40.0M for 2025). The company was in compliance as of June 30, 2025.
• Legal Contingencies: The company faces product liability litigation. Management estimates a probable loss range of $1.65M–$1.95M for one set of cases and $1.3M–$1.5M for another, with accruals recorded. There is a risk that damages could exceed insurance coverage limits.
• Tariffs & Inflation: The company is monitoring potential tariffs on imports from the EU, Canada, Mexico, and China, which could impact gross margins. Inflationary pressures on raw materials and labor remain a risk.

Investor Verification Checklist

• Debt Covenant Compliance: Verify if the company meets the $37.0M Advanced Energy revenue target and $40.0M operating expense cap for 2025 to avoid default on the Perceptive Credit Agreement.
• AYON Launch Execution: Monitor the commercial uptake of the AYON system in H2 2025 and the timing of the additional 510(k) submission for power liposuction.
• Litigation Exposure: Review updates on product liability claims to ensure actual losses do not exceed the accrued amounts or insurance coverage limits.
• Cash Burn Rate: Assess the sustainability of the current cash position ($29.3M) given the recurring net losses and the need to fund operations without immediate access to new capital.
• OEM Segment Recovery: Evaluate the trajectory of the OEM segment, which has seen significant revenue declines, to determine if the relationship with Symmetry Surgical is stabilizing.